Intravitreal bevacizumab (Avastin) in the treatment of macular edema secondary to retinal vein occlusion.
OBJECTIVE
To evaluate efficacy and safety of intravitreal injections of bevacizumab in the treatment of macular edema secondary to retinal vein occlusion (RVO).


METHODS
Prospective study, noncomparative, interventional case series. Twelve consecutive patients (12 eyes) with macular edema associated with nonischemic retinal vein occlusion were treated with intravitreal bevacizumab (1.25 mg). All subjects underwent standardized ophthalmic evaluation at baseline and at weeks 1, 4, 12, and 24, consisting of visual acuity (VA) measurement using ETDRS charts, and imaging with ocular coherence tomography evaluating changes in foveal thickness (FT) and macular volume (MV).


RESULTS
The median age was 66 years (+/- 4.16), and the median duration of symptoms was 4 months (+/- 1.81). There were six cases of inferior branch vein occlusion and six cases of superior branch retinal vein occlusion. Mean VA improved from 1.32 +/- 0.24 (logMAR values) at baseline to 0.8 +/- 0.15 (p = 0.0003) at the 6-month follow-up. The macular edema responded promptly, and a trend to restoration of normal macular anatomy was observed at by the seventh day. Mean FT improved from 615.50 +/- 116.29 microns to 420 +/- 72.53 microns (p = 0.001), and the mean MV improved from 19.81 +/- 2.31mm3 to 9.23 +/- 1.38 (p = 0.0001) at the 6-month follow-up.
Gutiérrez
Juan Carlos Mesa
JC
Department of Ophthalmology, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain.
Barquet
Luis Arias
LA
Caminal
Josep Maria
JM
Mitjana
Almolda
Sergi Prades
SP
Domènech
Nùria Planas
NP
Goita
Octavi Pujol
OP
Caso
Marc Rubio
MR
Ginebreda
Jorge Arruga
JA